Natera Signatera MCC Study: 90% Sensitivity, 13.5x Revenue

Natera (NTRA) closed July 25 at $261.99, giving the company a $37.5 billion market cap. That valuation rests on a simple thesis: Signatera, the company’s tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, is becoming the standard of care for cancer surveillance. A new study in JAMA Dermatology adds another data point to that thesis. The question is whether the stock already reflects it.

The MCC Study: 90% vs 55%

The study, published July 22 in JAMA Dermatology, compared Signatera to the standard Merkel cell polyomavirus antibody test (AMERK) for predicting recurrence in Merkel cell carcinoma (MCC), a rare but aggressive skin cancer. The results were clear. Signatera achieved 90% sensitivity versus 55% for AMERK. Patients who tested Signatera-positive had up to a 20-fold higher risk of recurrence (hazard ratio: 20). The study analyzed 169 patients and found Signatera detected relapse earlier than standard imaging (Natera press release).

This is a meaningful clinical result. MCC has a high recurrence rate, and early detection matters because delayed treatment is often fatal. A test that catches 90% of recurrences versus 55% for the standard approach gives oncologists a real tool to stratify patients for adjuvant therapy. The 20x recurrence risk for Signatera-positive patients is clinically actionable: it identifies a high-risk population that may benefit from closer surveillance or earlier intervention.

But MCC is a small indication. The US sees roughly 3,000 cases per year. This study will not move Natera’s revenue needle directly. What it does is add to the 350-plus peer-reviewed publications supporting Signatera across oncology, reinforcing the test’s clinical utility and competitive position.

Why Each New Indication Matters

Signatera is already reimbursed for colorectal cancer and breast cancer surveillance. Each new cancer type where the test demonstrates clinical utility expands the addressable market without requiring new R&D investment. The test is a CLIA-certified lab-developed test. Natera does not need a new FDA approval for each indication. It needs payer coverage, and payer coverage follows publication.

This is the flywheel: publish data, get coverage, volume grows, revenue grows, publish more data. The MCC study is one turn of that wheel. The Q1 2026 earnings deck noted record sequential growth for Signatera, with approximately 250,000 clinical oncology units processed in the quarter, up 55% year over year. The MRD test run rate has crossed 1 million units annually.

The Competitive Position

Natera holds approximately 80% of the US MRD testing market. Guardant Health (GH) is the primary competitor, with a liquid biopsy portfolio focused on treatment selection and residual disease. Guardant’s gross margin runs around 62%, compared to Natera’s 64.7% in Q1 2026. Natera processed over 1 million total tests in a single quarter for the first time in Q1 2026. Guardant is growing revenue at 48% year over year based on Q1 2026 data.

The gap between Natera and Guardant in MRD is not just market share. It is publication depth. Natera’s 350-plus publications dwarf the competition. Each paper, like the MCC study, makes it harder for a competitor to displace Signatera as the default MRD test. Oncologists are creatures of habit. Once they adopt a test supported by extensive literature, switching costs are high.

For investors trying to understand how to evaluate clinical data like this, our guide to reading clinical trial press releases breaks down how to separate meaningful endpoints from headline spin.

The Valuation Problem

Here is where I get cautious. Natera’s Q1 2026 revenue was $696.6 million, up 38.8% year over year. Full-year 2025 revenue was approximately $2.3 billion. The 2026 guidance is $2.74 to $2.82 billion. At $37.5 billion market cap, that puts Natera at roughly 13.5x forward revenue.

For a diagnostics company growing 39% with 65% gross margins, that multiple is not insane. But it leaves no room for deceleration. If growth slows from 39% to 25% in 2027, the multiple compresses hard. Management raised 2026 guidance by $120 million at the midpoint, which is encouraging. But the stock is up 14% year to date, from $228.84 in January to $261.99 now. Some of the good news is already priced in.

Compare Natera to a revenue-generating biotech comp in a different therapeutic area. Gilead (GILD) trades at roughly 3x revenue with $28 billion in annual sales. Natera trades at 13.5x revenue with $2.8 billion in expected 2026 sales. The difference is growth: Natera is growing 39%, Gilead is growing in the mid-single digits. But 13.5x revenue means the market expects Natera to sustain 30%+ growth for several more years.

The comp that matters more is Guardant Health. Guardant’s Q1 2026 revenue grew 48% year over year, actually faster than Natera’s 39%. Guardant trades at roughly 6x forward revenue, less than half Natera’s multiple, despite growing faster. The market gives Natera the premium because of its dominant 80% MRD market share and deeper publication record. But if Guardant narrows that gap, the multiple premium narrows with it. A 13.5x multiple at 39% growth looks different if the competitor is growing 48% and trading at 6x.

The Q3 2026 FDA calendar tracks the binary catalysts that move biotech stocks. Natera is not a PDUFA play. Its catalysts are publication-driven, not approval-driven. That makes the stock less binary but also means each publication, like the MCC study, needs to keep the growth narrative alive.

The Numbers Behind Signatera

Signatera’s average selling price (ASP) is improving. Management guided to an exit ASP of approximately $1,275 in 2026. With 250,000 clinical oncology units in Q1 and growing 55% year over year, the MRD franchise alone could generate $1.3 to $1.5 billion in annual revenue at current ASPs and growth rates.

The total company revenue is guided to $2.74 to $2.82 billion for 2026. Signatera is the growth engine, but Natera also sells Panorama (non-invasive prenatal testing), Horizon (carrier screening), and Prospera (organ transplant rejection). The women’s health franchise set a record in Q1 2026, and Fetal Focus is ramping. The diversity of the portfolio reduces single-product risk.

Gross margin expanded to 64.7% in Q1 2026 from 63.1% a year ago. Management guides to 64% to 66% for the full year. Operating loss was $93.5 million in Q1, which sounds bad but is manageable for a company with $1.09 billion in cash and positive cash flow guidance for 2026. R&D spending jumped 63% year over year to $210.7 million as Natera invests in clinical trials to expand Signatera’s evidence base. That investment is the flywheel in action: spend on trials, publish data, get coverage, grow volume. The MCC study is one output of that R&D machine.

The Risk I Am Watching

The biggest risk is ASP compression from Medicare and private payers. Signatera’s reimbursement is not guaranteed indefinitely. If Medicare reduces the rate or imposes coverage restrictions, the ASP could decline. Management’s $1,275 exit ASP assumes favorable coverage decisions. Any adverse coverage policy from CMS could cut into the growth narrative.

The second risk is competition. Guardant Health is not standing still. Guardant’s revenue grew 48% year over year in Q1 2026, faster than Natera’s 39%. If Guardant closes the publication gap and gains MRD share, Natera’s premium multiple is vulnerable.

The third risk is valuation. At 13.5x forward revenue, the stock prices in near-flawless execution. Any growth miss, any ASP compression, any competitive loss of share, and the multiple compresses. The downside is asymmetric to the upside at current levels.

Verdict

The MCC study is a legitimate clinical win. Signatera’s 90% sensitivity versus 55% for AMERK, with a 20x recurrence risk for positive patients, is the kind of data that expands clinical adoption. Natera’s MRD moat is deep, and each publication makes it deeper.

But at $37.5 billion market cap and 13.5x forward revenue, the stock is priced for perfection. I would not buy Natera at $262 expecting the MCC study to drive a re-rating. The study is already reflected in the 14% year-to-date gain. The risk-reward is balanced at best. If you own Natera, the MCC data reinforces the thesis. If you do not own it, I would wait for a pullback below $230, which would bring the multiple closer to 11x revenue. That is still expensive, but it leaves more room for the inevitable growth deceleration.

The MRD market is real and growing. Natera is the leader. But leadership does not mean the stock is a buy at any price. At $262, it is not.